A Phase Ib Multicenter Dose-Finding and Safety Study of Venetoclax and Obinutuzumab in Patients With Relapsed or Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2017
At a glance
- Drugs Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Genentech
- 17 Nov 2017 Planned End Date changed from 2 Apr 2019 to 27 Apr 2018.
- 17 Nov 2017 Planned primary completion date changed from 2 Apr 2019 to 27 Apr 2018.
- 01 Nov 2017 According to a Genentech media release, data from the study will be presented at the American Society of Hematology (ASH) 2017 Annual Meeting.